Austrian Academy of Sciences CeMM Research Center for Molecular Medicine Vienna Austria

Bristol Genetics Laboratory Southmead Hospital Bristol UK

CLIP Childhood Leukaemia Investigation Prague Department of Paediatric Haematology and Oncology 2nd Faculty of Medicine Charles University and University Hospital Motol Prague Czech Republic

Department of Hematology University Hospital Zürich Switzerland

Department of Immunology Laboratory Medical Immunology Erasmus MC University Medical Center Rotterdam Rotterdam Netherlands

Department of Immunology Leiden University Medical Center Leiden the Netherlands

Department of Internal Medicine 2 University Hospital Schleswig Holstein Kiel Germany

Department of Pediatric Hematology and Oncology Charité Universitätsmedizin Berlin Berlin Germany

German Cancer Consortium Heidelberg Germany

Hematology Division Department of Molecular Biotechnology and Health Sciences University of Torino Torino Italy

Hematology Laboratory Saint Louis Hospital Assistance Publique Hôpitaux de Paris Paris France

St Anna Children's Cancer Research Institute Vienna Austria

Tettamanti Cente Fondazione IRCCS San Gerardo dei Tintori Monza Italy

Zobrazit více v PubMed

van der Velden VHJ, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grumayer ER, et al. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia. 2007;21:604–11. doi: 10.1038/sj.leu.2404586. PubMed DOI

Fronkova E, Muzikova K, Mejstrikova E, Kovac M, Formankova R, Sedlacek P, et al. B-cell reconstitution after allogeneic SCT impairs minimal residual disease monitoring in children with ALL. Bone Marrow Transpl. 2008;42:187–96. doi: 10.1038/bmt.2008.122. PubMed DOI

Kotrova M, van der Velden VHJ, van Dongen JJM, Formankova R, Sedlacek P, Brüggemann M, et al. Next-generation sequencing indicates false-positive MRD results and better predicts prognosis after SCT in patients with childhood ALL. Bone Marrow Transpl. 2017;52:962–8. doi: 10.1038/bmt.2017.16. PubMed DOI

van der Velden VHJ, Wijkhuijs JM, van Dongen JJM. Non-specific amplification of patient-specific Ig/TCR gene rearrangements depends on the time point during therapy: implications for minimal residual disease monitoring. Leukemia. 2008;22:641–4. doi: 10.1038/sj.leu.2404925. PubMed DOI

Schwinghammer C, Koopmann J, Chitadze G, Karawajew L, Brüggemann M, Eckert C. A new view on minimal residual disease quantification in acute lymphoblastic leukemia using droplet digital PCR. J Mol Diagn. 2022;24:856–66. doi: 10.1016/j.jmoldx.2022.04.013. PubMed DOI

Kotrová M, Koopmann J, Trautmann H, Alakel N, Beck J, Nachtkamp K, et al. Prognostic value of low-level MRD in adult acute lymphoblastic leukemia detected by low- and high-throughput methods. Blood Adv. 2022;6:3006–10. doi: 10.1182/bloodadvances.2021006727. PubMed DOI PMC

Svaton M, Skotnicova A, Reznickova L, Rennerova A, Valova T, Kotrova M, et al. NGS better discriminates true MRD positivity for the risk stratification of childhood ALL treated on an MRD-based protocol. Blood. 2023;141:529–33. doi: 10.1182/blood.2022017003. PubMed DOI PMC

Kotrova M, Muzikova K, Mejstrikova E, Novakova M, Bakardjieva-Mihaylova V, Fiser K, et al. The predictive strength of next-generation sequencing MRD detection for relapse compared with current methods in childhood ALL. Blood. 2015;126:1045–7. doi: 10.1182/blood-2015-07-655159. PubMed DOI PMC

Ladetto M, Brüggemann M, Monitillo L, Ferrero S, Pepin F, Drandi D, et al. Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders. Leukemia. 2014;28:1299–307. doi: 10.1038/leu.2013.375. PubMed DOI

van der Velden VHJ, Dombrink I, Alten J, Cazzaniga G, Clappier E, Drandi D, et al. Analysis of measurable residual disease by IG/TR gene rearrangements: quality assurance and updated EuroMRD guidelines. Leukemia. 2024. 10.1038/s41375-024-02272-0. PubMed PMC

Minimal residual disease detection for acute lymphoblastic leukaemia in peripheral blood-Are we there yet?

Analysis of measurable residual disease by IG/TR gene rearrangements: quality assurance and updated EuroMRD guidelines